RIPK1 and systemic inflammatory response syndrome: A representative of this group, compound PN10, is characterized by ~20-fold greater antinecroptotic activity and high RIP1-selectivity, being also efficient at a low dose (0.4 mg/kg) in the mouse SIRS (systemic inflammatory response syndrome) model [60].